KEYNOTE-B15 compared perioperative enfortumab vedotin plus pembrolizumab against neoadjuvant cisplatin-based chemotherapy in cisplatin-eligible MIBC, using event-free survival as the primary endpoint.
Dr. Matthew Galsky spoke with CURE about the KEYNOTE-B15 trial results and their potential impact on muscle-invasive bladder cancer care. At the 2026 ASCO Genitourinary Cancers Symposium, the ...
The hourlong program "Why Can't We Cure Cancer? A National Conversation" comes as a follow-up to NewsNation's November ...
A high percentage of bladder cancers can be cured if they are found early. Once cancer spreads outside the bladder, it is much harder to treat. That’s why it’s important to first bring up any ...
SurvivorNet on MSN
A breakthrough for muscle-invasive bladder cancer: Padcev plus Keytruda drug combo could transform treatment around surgery
Nearly 200,000 Americans are living with muscle-invasive bladder cancer (MIBC)—and after decades with few major advances, newly presented data may signal a turning point in how the disease is treated.
Individuals share their journeys battling cancer and their experiences with groundbreaking immunotherapy treatments.
SurvivorNet on MSN
Diagnosing muscle-invasive bladder cancer: The initial work-up
When a doctor suspects bladder cancer, they will order a series of tests which may include urine tests (urinalysis or urine ...
Colorblindness may be doing more than making traffic lights confusing — it could also be hiding a life-threatening warning sign. Researchers analyzing millions of medical records found that people ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results